Literature DB >> 30589380

Diagnostic Outcome of Image-Guided Percutaneous Core Needle Biopsy of Sclerotic Bone Lesions: A Meta-Analysis.

Chong Hyun Suh1, Seong Jong Yun2.   

Abstract

OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the diagnostic outcome (diagnostic yield and accuracy) of image-guided percutaneous core needle biopsy (CNB) of sclerotic bone lesions.
MATERIALS AND METHODS: A computerized search of the PubMed and EMBASE databases was performed to identify relevant original articles on the use of image-guided percutaneous CNB of sclerotic bone lesions. The pooled proportions of the diagnostic yield and pooled accuracy estimates were assessed using random-effects modeling. We also performed subgroup analyses of the diagnostic yield according to the drill systems (battery-powered vs manual). Heterogeneity among studies was determined using the inconsistency index (I2). Meta-regression analyses were performed to evaluate the potential sources of heterogeneity.
RESULTS: Fifteen eligible studies, involving 969 sclerotic bone lesions for diagnostic yield, and 242 sclerotic bone lesions for diagnostic accuracy, were included. The pooled proportion of the diagnostic yield of image-guided percutaneous CNB of sclerotic bone lesions was 74% (95% CI, 62-84%), and the pooled accuracy estimate for differentiation between benign and malignant lesions was 87% (95% CI, 77-93%). In the subgroup analysis, the pooled proportion of the diagnostic yield of the battery-powered drill system (76.7% [95% CI, 64.0-85.8%]) was higher than that of the manual drill system (65.2% [95% CI, 58.0-71.8%]). In the meta-regression analyses, no variables were significantly different (p = 0.13-0.93).
CONCLUSION: In conclusion, we determined that image-guided percutaneous CNB of sclerotic bone lesions is an accurate diagnostic technique with good diagnostic yield, particularly when the battery-powered bone biopsy system is used.

Entities:  

Keywords:  bone neoplasms; core needle biopsy; data accuracy; meta-analysis; sclerosis

Year:  2018        PMID: 30589380     DOI: 10.2214/AJR.18.20243

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

Review 1.  Review article: the current status of CT-guided needle biopsy of the spine.

Authors:  Asif Saifuddin; Valentina Palloni; Hannah du Preez; Syed Ehtasham Junaid
Journal:  Skeletal Radiol       Date:  2020-08-19       Impact factor: 2.199

Review 2.  Minimally Invasive Interventional Procedures for Metastatic Bone Disease: A Comprehensive Review.

Authors:  Nicolas Papalexis; Anna Parmeggiani; Giuliano Peta; Paolo Spinnato; Marco Miceli; Giancarlo Facchini
Journal:  Curr Oncol       Date:  2022-06-07       Impact factor: 3.109

Review 3.  Chondroblastoma of the patella with secondary aneurysmal bone cyst, an easily misdiagnosed bone tumor:a case report with literature review.

Authors:  Jianping Zheng; Ningkui Niu; Jiandang Shi; Xu Zhang; Xi Zhu; Jiali Wang; Changhao Liu
Journal:  BMC Musculoskelet Disord       Date:  2021-04-23       Impact factor: 2.362

4.  Validity of negative bone biopsy in suspicious bone lesions.

Authors:  Mine B Lange; Lars J Petersen; Michael B Nielsen; Helle D Zacho
Journal:  Acta Radiol Open       Date:  2021-07-27

5.  Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.

Authors:  Ricardo Donners; Nicos Fotiadis; Ines Figueiredo; Matthew Blackledge; Daniel Westaby; Christina Guo; Maria de Los Dolores Fenor de la Maza; Dow-Mu Koh; Nina Tunariu
Journal:  Eur Radiol       Date:  2022-07-26       Impact factor: 7.034

6.  Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.

Authors:  Ricardo Donners; Ines Figueiredo; Nina Tunariu; Matthew Blackledge; Dow-Mu Koh; Maria de Los Dolores Fenor de la Maza; Khobe Chandran; Johann S de Bono; Nicos Fotiadis
Journal:  Eur Radiol       Date:  2022-01-29       Impact factor: 7.034

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.